60373-71-9 Usage
Uses
Used in Pharmaceutical Research:
1-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1,3-dihydro-benzoimidazol-2-one is used as a research compound for exploring its potential biological activities. Its unique structure suggests it may be involved in enzyme inhibition or receptor modulation, which are key mechanisms in various pharmacological interventions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1,3-dihydro-benzoimidazol-2-one is used as a lead compound for the development of new drugs. Its structural features make it a promising candidate for further optimization and modification to enhance its therapeutic properties and target specific diseases.
Used in Drug Design and Development:
1-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1,3-dihydro-benzoimidazol-2-one is utilized in drug design and development processes to create novel therapeutic agents. Its potential as a pharmacological agent is being investigated for various applications, including the treatment of diseases where enzyme inhibition or receptor modulation is beneficial.
Check Digit Verification of cas no
The CAS Registry Mumber 60373-71-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,3,7 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 60373-71:
(7*6)+(6*0)+(5*3)+(4*7)+(3*3)+(2*7)+(1*1)=109
109 % 10 = 9
So 60373-71-9 is a valid CAS Registry Number.
InChI:InChI=1/C19H19N3O/c23-19-20-17-8-4-5-9-18(17)22(19)16-10-12-21(13-11-16)14-15-6-2-1-3-7-15/h1-10H,11-14H2,(H,20,23)
60373-71-9Relevant academic research and scientific papers
Rearrangement of spiro-benzimidazolines: preparation of N-alkenyl- and N-alkyl-benzimidazol-2-ones
Kuethe, Jeffrey T.,Varon, Jack,Childers, Karla G.
, p. 11489 - 11502 (2008/03/13)
A synthetically useful protocol has been developed for the preparation of highly functionalized N-alkenyl-benzimidazol-2-ones. Reaction of commercially available o-phenylenediamines with variously substituted cyclic ketones provides spiro-benzimidazolines. Treatment of these spiro-benzimidazolines with triphosgene in the presence of potassium carbonate results in rapid rearrangement and formation of N-alkenyl-benzimidazol-2-ones in modest to excellent yield for the two-step sequence. Extension of this methodology toward the preparation of a μ opiate receptor antagonist and droperidol, a potent antiemetic and antipsychotic agent, currently a marketed pharmaceutical is also described. Upon treatment of spiro-benzimidazolines with triphosgene in the presence of sodium triacetoxyborohydride, N-alkyl-benzimidazol-2-ones were formed.
